ReviewClinical and experimental immunology2003
Dendritic cells, T cell tolerance and therapy of adverse immune reactions.
Review in Clinical and experimental immunology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 76 citations in OpenAlex.
- Hybrid computational modeling demonstrates the utility of simulating complex cellular networks in type 1 diabetes.PLoS computational biology · 2021Article
- CD8αα+MHC Class II+ Cell with the Capacity To Terminate Autoimmune Inflammation Is a Novel Antigen-Presenting NK-like Cell in Rats.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Overexpression of Jagged-1 combined with blockade of CD40 pathway prolongs allograft survival.Immunology and cell biology · 2015Article
- Dendritic cell subsets in type 1 diabetes: friend or foe?Frontiers in immunology · 2013Review
- MRI tracking of macrophages labeled with glucan particles entrapping a water insoluble paramagnetic Gd-based agent.Molecular imaging and biology · 2013Article
- Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation.Clinical & developmental immunology · 2012Review
- Epigallocatechin gallate delays the onset of type 1 diabetes in spontaneous non-obese diabetic mice.The British journal of nutrition · 2011Article
- Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking.Cytotherapy · 2010Article
- Article
- Designing the optimal vaccine: the importance of cytokines and dendritic cells.The open vaccine journal · 2010Article
- Alpha versus beta: are we on the way to resolve the mystery as to which is the endogenous ligand for natural killer T cells?Clinical and experimental immunology · 2009Article
- Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells.Journal of leukocyte biology · 2008Article
- TH2 cells in the pathogenesis of airway remodeling: regulatory T cells a plausible panacea for asthma.Immunologic research · 2006Review
- Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses.Clinical and experimental immunology · 2005Article
- Fc gamma R expression on NK cells influences disease severity in rheumatoid arthritis.Genes and immunity · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Dendritic cells (DC) are uniquely able to either induce immune responses or to maintain the state of self tolerance. Recent evidence has shown that the ability of DC to induce tolerance in the steady state is critical to the prevention of the autoimmune response. Likewise, DC have been shown to induce several type of regulatory T cells including Th2, Tr1, Ts and NKT cells, depending on the maturation state of the DC and the local microenvironment. DC have been shown to have therapeutic value in models of allograft rejection and autoimmunity, although no success has been reported in allergy. Several strategies, including the use of specific DC subsets, genetic modification of DC and the use of DC at various maturation stages for the treatment of allograft rejection and autoimmune disease are discussed. The challenge for the future use of DC therapy in human disease is to identify the appropriate DC for the proposed therapy; a task made more daunting by the extreme plasticity of DC that has recently been demonstrated. However, the progress achieved to date suggests that these are not insurmountable obstacles and that DC may become a useful therapeutic tool in transplantation and autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.